The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to the drug being described as subpotent.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has recalled levothyroxine sodium tablets across the United States. The recall affects multiple dosage strengths of the thyroid medication.
Coverage from NBC 7 San Diego, WTHR, News4JAX, WSB-TV, and EatingWell emphasizes that the medication has been identified as a subpotent drug. Reports highlight that the recall is nationwide in scope.
Further updates are expected regarding specific affected batches and guidance for patients using these medications.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What medication is being recalled?
Levothyroxine sodium tablets are being recalled.
Why was the recall issued?
The thyroid medication was described as a 'subpotent drug'.
What is the geographic scope of the recall?
The recall is nationwide, affecting dosage strengths across the U.S.
Coverage (6)
- Thyroid medication described as 'subpotent drug' recalled by FDA WKYC · 4h ago
- Recall alert: Thyroid medication Levothyroxine recalled nationwide WSB-TV · 4h ago
- Thyroid drug recall affects multiple dosage strengths across U.S. News4JAX · 4h ago
- FDA recalls levothyroxine sodium tablets. Here's what to know NBC 7 San Diego · 4h ago
- Thyroid medication described as 'subpotent drug' recalled by FDA WTHR · 4h ago
- The FDA Issued a Recall on Thyroid Medication Nationwide EatingWell · 4h ago broke it first
People, places & organizations
Topics
Related trends
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.
Compounded GLP-1 drugs creating concern among doctors and FDA
Doctors and the FDA are warning against the use of compounded GLP-1 weight-loss drugs due to potential health risks and troubling study findings.
FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
The FDA has approved Simtriyo (centanafadine), the first new-class ADHD medication for children and adults in decades.
Cyclospora outbreak has many changing eating habits, CBS News poll finds; mixed and partisan confidence in FDA
A Cyclospora outbreak is shifting consumer eating habits and fueling a surge in demand for local produce and home-grown greens.
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly is planning a Q1 2027 FDA application for retatrutide following new data on weight loss and A1C improvements.
Taylor Farms CEO breaks silence over explosive diarrhea outbreak as class-action lawsuit filed
Taylor Farms faces a class-action lawsuit and operational shutdowns following an outbreak of cyclosporiasis.